These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7132978)

  • 41. [Growth disorders. Treatments].
    Butin L; Pauget P; Butel J
    Soins Chir; 1990; (112-113):10-2. PubMed ID: 2237019
    [No Abstract]   [Full Text] [Related]  

  • 42. Androgen replacement therapy.
    Osterman J
    Curr Ther Endocrinol Metab; 1994; 5():286-91. PubMed ID: 7704734
    [No Abstract]   [Full Text] [Related]  

  • 43. [Anatomic substratum of therapeutic effects obtained in chorioepithelioma by hormonal treatment (A.C.T.H. plus estrogens, testosterone plus estrogens)].
    Badarau L; Gavrilita L; Negura Marderos A
    Rev Fr Gynecol Obstet; 1968; 63(1):43-51. PubMed ID: 4312490
    [No Abstract]   [Full Text] [Related]  

  • 44. [Treatment of constitutional developmental retardation with oxandrolone].
    Novoa Mogollón J; Salto Hernández L; Pérez Pérez C; Alcáñiz Ferrando J; Uriarte Arana A; Moreno Puertas C; Barceló Lucerga B
    Rev Clin Esp; 1981 Sep; 162(6):259-62. PubMed ID: 7330320
    [No Abstract]   [Full Text] [Related]  

  • 45. Warning issued for testosterone products.
    AIDS Patient Care STDS; 2009 Jun; 23(6):491. PubMed ID: 19530320
    [No Abstract]   [Full Text] [Related]  

  • 46. Disorders of sex development: hormonal management in adolescence.
    Bertelloni S; Dati E; Baroncelli GI
    Gynecol Endocrinol; 2008 Jun; 24(6):339-46. PubMed ID: 18584414
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Irreversible physical changes.
    Jacobeit J; Wüsthof A
    Dtsch Arztebl Int; 2009 May; 106(18):318; author reply 318. PubMed ID: 19547648
    [No Abstract]   [Full Text] [Related]  

  • 48. Predicting growth in response to growth hormone treatment.
    Ranke MB; Lindberg A
    Growth Horm IGF Res; 2009 Feb; 19(1):1-11. PubMed ID: 18824380
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Growth hormone and estrogen: a clinician's approach.
    Cook DM
    J Pediatr Endocrinol Metab; 2004 Sep; 17 Suppl 4():1273-6. PubMed ID: 15506073
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treatment of peripheral arteriosclerotic circulation disorders with sex hormones].
    Meng W; Meng S
    Z Arztl Fortbild (Jena); 1968 Dec; 62(24):1306-9. PubMed ID: 5714204
    [No Abstract]   [Full Text] [Related]  

  • 51. The risks of androgen treatment in postmenopausal women remain controversial: a need for equitable comparisons.
    Pru JK
    Menopause; 2009; 16(3):430-1. PubMed ID: 19265724
    [No Abstract]   [Full Text] [Related]  

  • 52. Final height outcome of growth hormone-deficient patients treated since less than five years of age.
    De Luca F; Maghnie M; Arrigo T; Lombardo F; Messina MF; Bernasconi S
    Acta Paediatr; 1996 Oct; 85(10):1167-71. PubMed ID: 8922077
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Hypothyroidism in child].
    Polak M
    Rev Prat; 2005 Dec; 55(19):2173-80. PubMed ID: 16544929
    [No Abstract]   [Full Text] [Related]  

  • 54. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women.
    Tamimi RM; Hankinson SE; Chen WY; Rosner B; Colditz GA
    Arch Intern Med; 2006 Jul; 166(14):1483-9. PubMed ID: 16864758
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Hormonal "rejuvenation". Warning your patients from false claims!].
    Brückel J
    MMW Fortschr Med; 2002 Sep; 144(39):24-7. PubMed ID: 12422680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Results of treatment with recombinant human growth hormone in children with growth retardation in end-stage renal disease].
    Sieniawska M; Pańczyk-Tomaszewska M; Ziółkowska H; Jedrzejowski A; Leszczyńska B; Dyras P; Kałuzyńska A; Makulska I; Pietrzyk JA; Rubik J; Siteń G; Stachowski J; Szprynger K; Zurowska A; Roszkowska-Blaim M
    Pol Merkur Lekarski; 2001 Apr; 10(58):263-6. PubMed ID: 11434172
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of puberty in relation to L-carnitine and hormonal replacement therapy in beta-thalassemic patients.
    El Beshlawy A; Mohtar G; Abd El Ghafar E; Abd El Dayem SM; El Sayed MH; Aly AA; Farok M
    J Trop Pediatr; 2008 Dec; 54(6):375-81. PubMed ID: 18647801
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rationale for growth hormone therapy in children with chronic kidney disease.
    Greenbaum LA; Del Rio M; Bamgbola F; Kaskel F
    Adv Chronic Kidney Dis; 2004 Oct; 11(4):377-86. PubMed ID: 15492975
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Prediction of permanent body height in tall children].
    Butenandt O
    Med Klin Prax; 1982 May; 77(11):20-5. PubMed ID: 7099102
    [No Abstract]   [Full Text] [Related]  

  • 60. Retesting of patients with isolated growth hormone deficiency (IGHD) using provocative tests and reevaluation of them after termination of therapy.
    Büyükgebiz A; Böber E
    J Pediatr Endocrinol Metab; 2000 Feb; 13(2):223-4. PubMed ID: 10711671
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.